---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-001273"
form_type: "8-K"
ticker: "VNDA"
cik: "0001347178"
company_name: "Vanda Pharmaceuticals Inc."
filed_at: "2026-01-08T23:59:59+00:00"
generated_at: "2026-05-16T11:11:17.418519+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# FDA rejects Vanda's HETLIOZ sNDA for jet lag disorder after expedited re-review

## Summary
- FDA concluded sNDA cannot be approved in current form, citing phase advance protocols not sufficiently analogous to actual jet travel.
- FDA acknowledged positive efficacy from controlled trials but said data do not provide substantial evidence of effectiveness.
- Vanda respectfully disagrees and will pursue all appropriate avenues for approval; notes prior D.C. Circuit ruling set aside FDA refusal.
- Expedited re-review was completed by Jan 7, 2026 under collaborative framework agreement from October 2025.
- HETLIOZ (tasimelteon) currently approved for non-24-hour sleep-wake disorder; jet lag would be new indication.

## SEC filing metadata
- accession: 0001628280-26-001273
- form_type: 8-K
- ticker: VNDA
- cik: 0001347178
- company_name: Vanda Pharmaceuticals Inc.
- filed_at: 2026-01-08T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347178/000162828026001273/0001628280-26-001273-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347178/000162828026001273/vnda-20260107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-001273
- JSON: https://secwatch.observer/filing/0001628280-26-001273.json
- Plain text: https://secwatch.observer/filing/0001628280-26-001273.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.